Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Roche will pay Boston-based Jnana Therapeutics $40 million up front as part of a drug discovery pact that spans targets relevant in immunology and neuroscience. Stuart Schreiber and Ramnik Xavier, scientists at Broad Institute of MIT and Harvard, founded Jnana in 2017 to develop small molecules that target members of a family of 450 proteins, called solute carriers (SLC), that shuttle metabolites in and out of cells.
This article has been sent to the following recipient: